We’re developing Sepranolone, a novel therapy for the treatment of menstrual migraine and Tourette syndrome. Sepranolone is an endogenous compound, produced naturally in the brain. It modulates the effects of the potent, behavior-altering neurosteroid Allopregnanolone.

Allopregnanolone is implicated in a wide range of stress-related and compulsion-related conditions—from menstrual migraine and Tourette, to PMDD, OCD, PTSD, compulsive gambling and addiction. Sepranolone has been developed from over 40 years’ neuroendocrinological research.

Watch our Presentation of Phase IIb PMDD study results here

Join our Sepranolone for Menstrual Migraine study

Latest Press Release

Asarina Pharma AB (publ) Interim Report Q1 2020 released

Latest News

SAVE THE DATE: Asarina Pharma R&D Day – Thursday 26 March


Whilst few have heard of the highly potent neurosteroid Allopregnanolone, millions suffer from the effect of it. Elevated Allopregnanolone (ALLO) levels or a heightened sensitivity to ALLO exist in patients with menstrual migraine, Tourette, catamenial epilepsy, OCD, PTSD, stress-related fatigue, compulsive gambling and addiction.

The body defends us from the negative impact of ALLO with an endogenous compound that modulates and inhibits its effects—Sepranolone.

Sepranolone was first developed and synthesized as a therapeutic compound by Asarina Pharma through the research of its Founder and CSO Professor Torbjörn Bäckström.


“For five days every month normal life grinds to a halt… and disabling pain takes over.”
‘Therese’, 38, Germany​

Menstrual Migraine is a disabling form of migraine with severe, prolonged attacks. It impacts approx. 50 million women worldwide. MM is often resistant to current standard treatments, including. 

Yet there has never been a specific therapy to treat it. Until now. Our Phase IIA trial for Sepranolone—a prophylactic treatment designed to prevent Menstrual Migraine symptoms from even occurring—is now underway.


Tourette’s syndrome is a cruel condition typically striking first between the ages of 39 years old. Yet many current treatments, like the anti-psychotic Haldol, have severe side effects ranging from blurred vision, nausea and diarrhoea to  involuntary movement disorder, irregular heartbeat and even renal failure. 


In May 2019 Asarina Pharma demonstrated in a preclinical animal study that Sepranolone reduced tics on a par with Haldol, without inducing any motor side effects.

Asarina Pharma CEO Peter Nordkild: “This is a new approach, and a safe one. There are no neurosteroid-based medications currently being used to treat TS. A positive result would be extremely promising for patients, and indicate that Sepranolone could potentially play a part in treating a range of other ALLO-related stress disorders.”